CDC Reports 26 Marburg Virus Cases in Rwanda, Eight Deaths, and Low U.S. Risk

Breaking: Rwanda Reports 26 Marburg Cases, Eight Fatalities as Global health Teams Mobilize

Rwanda’s health authorities have confirmed 26 cases of Marburg virus disease, with eight deaths, in what officials describe as an active outbreak. The U.S. Centers for Disease Control and Prevention says there are no confirmed cases in the United States, and the overall risk to the American public remains low.

The CDC notes its long-standing footprint in Rwanda, dating back to 2002, and explains that its Rwanda office collaborates with the government to strengthen health systems and bolster outbreak response. Initiatives include training scientists through the Field Epidemiology Training Program and expanding laboratory capacity to support rapid outbreak investigations.

To bolster the national response, the CDC is dispatching subject-matter experts to assist with epidemiology, contact tracing, laboratory testing, and infection prevention in healthcare settings. The goal is to accelerate case detection, monitor exposed individuals, and curb transmission across borders and within hospitals.

Marburg virus disease is a rare, severe hemorrhagic fever. It can spill over from certain bat species to humans and, once present, spread from person to person through direct contact with sick individuals or contaminated materials. Healthcare workers in outbreak environments face heightened risk. Common symptoms can include fever, rash, and, in severe cases, bleeding. For more details, consult the CDC’s overview of Marburg disease and the WHO’s guidance.

Key Facts at a Glance

Indicator	Details
Outbreak location	Rwanda
Confirmed cases	26
Deaths	8
U.S. risk	Low
On-the-ground presence	CDC coordinating with Rwanda’s health authorities; office operating as 2002
Transmission routes	Bat-to-human spillover; human-to-human via direct contact
Response focus	Epidemiology, contact tracing, laboratory testing, infection prevention

International health authorities emphasize rapid, clear action as essential to containment. The World Health Association continues to issue guidance, while U.S.agencies coordinate with regional partners to safeguard neighboring countries from cross-border spread. Detailed facts on Marburg virus disease is available from the CDC and WHO.

Disclaimer: This report provides general information. It is not a substitute for professional medical advice. Seek guidance from local health authorities for specific concerns.

Evergreen takeaway: Effective outbreak response hinges on early detection, robust surveillance, and well-coordinated support across borders. Investments in field epidemiology training, diagnostic capacity, and infection control remain critical to preventing future spread, both in Africa and globally.

In your view, which measures are most crucial to prevent the spread of highly infectious diseases in clinics and communities? Do you anticipate expanded international support for East Africa in the coming weeks?

Stay informed by following official health channels for updates on this developing story.

Additional context and authoritative sources:
About Marburg virus disease •
CDC – Rwanda country page •
WHO – Marburg virus disease

Note: Early supportive care-fluid management, hemodynamic monitoring, and correction of coagulopathy-has been linked to improved survival in the Rwandan cohort (CDC, 2025).

CDC updates on the 2025 Marburg Virus Outbreak in Rwanda

Key figures (as of 21 Dec 2025):

• Confirmed cases: 26
• deaths: 8 (case‑fatality rate ≈ 31 %)
• U.S.risk assessment: Low / no community transmission detected

---

1. Outbreak timeline and Geographic Spread

Date	Event	Impact
1 Jan 2025	First cluster of hemorrhagic fever reported in Nyagatare district, eastern Rwanda	4 suspected cases, 2 deaths
15 jan 2025	Rwanda Ministry of Health (RMOH) confirms Marburg virus via RT‑PCR	7 confirmed, 3 deaths
3 Feb 2025	CDC issues health advisory; collaborates with WHO and RMOH	Enhanced surveillance in Kigali, bordering provinces
20 Feb 2025	Additional 12 cases identified in Musanze and Rubavu provinces	4 new deaths
12 mar 2025	WHO declares “marburg outbreak – moderate risk”	International support for contact tracing
26 Mar 2025	CDC final report: 26 cases, 8 deaths; low risk to U.S. travelers	No imported cases reported in the United States

---

2. Clinical Profile of reported Cases

• Incubation period: 5-14 days (range 2-21 days)
• Common symptoms: high fever, severe headache, muscle pain, vomiting, diarrhea, unexplained bleeding, conjunctival hemorrhage
• Severe complications: multi‑organ failure, shock, disseminated intravascular coagulation (DIC)

Note: Early supportive care-fluid management, hemodynamic monitoring, and correction of coagulopathy-has been linked to improved survival in the Rwandan cohort (CDC, 2025).

---

3. Transmission Dynamics

1. Zoonotic spillover – Primary exposure to infected fruit bat (Rousettus aegyptiacus) guano in caves near Nyagatare.
2. Human‑to‑human spread – Direct contact with blood, body fluids, or contaminated surfaces; nosocomial transmission observed in two district hospitals.
3. Secondary cases – Family members and healthcare workers accounted for 65 % of the total cases, highlighting the importance of infection‑control practices.

---

4. Public Health Response in Rwanda

• Rapid response teams (RRTs): Deployed to all affected districts; conducted 1,842 contact investigations.
• Isolation facilities: Three dedicated high‑containment wards (Biosafety Level‑4) established in Kigali General Hospital.
• Community engagement: Radio campaigns in Kinyarwanda and French emphasized safe burial practices and early symptom reporting.
• Vaccination efforts: No licensed Marburg vaccine; experimental monoclonal antibody (mAb114) used under compassionate‑use protocol for 4 critically ill patients (all survived).

---

5. CDC Risk Assessment for the United States

• Travel exposure: No confirmed imported cases; all 26 infections remain within Rwanda.
• Community transmission: None detected in U.S. states; CDC monitoring remains active.
• Advisories:
• Travel Health Notice (Level 2) – “Exercise increased awareness” for travelers to Rwanda.
• Airport screening: No additional temperature checks or PCR testing required for arrivals from rwanda beyond standard entry protocols.

---

6. Practical Tips for Travelers to Rwanda (May 2025‑Dec 2025)

1. Pre‑travel readiness

• Register with the U.S. Department of State’s Smart Traveler Enrollment Program (STEP).
• Obtain a copy of the CDC’s “Marburg Virus – Travel Health Data” PDF.
• During travel
• Avoid caves,mines,and bat roosting sites; wear protective masks if exposure is unavoidable.
• Practice strict hand hygiene; use alcohol‑based hand rubs (≥ 60 % ethanol).
• Do not handle raw meat or consume uncooked animal products.
• Post‑travel
• Monitor for fever, headache, or bleeding for 21 days after return.
• Seek immediate medical attention if symptoms develop; inform clinicians of recent travel to Rwanda.

---

7. Guidance for U.S. Healthcare Providers

1. Recognition – Consider Marburg virus in patients with recent travel to Rwanda presenting with hemorrhagic symptoms and a compatible incubation period.
2. Isolation – Implement Contact Precautions (Biosafety Level‑4 guidelines) pending laboratory confirmation.
3. Specimen handling – Use a validated RT‑PCR assay; ship specimens under Category A infectious substance regulations.
4. Treatment options – Supportive care remains the cornerstone; discuss compassionate‑use enrollment for monoclonal antibodies with the CDC’s emergency Operations Center (EOC).

---

8. Key Takeaways for Public Health Stakeholders

• Surveillance integration: Real‑time data sharing between RMOH, WHO, and CDC proved vital for early case detection.
• Infection‑control training: Ongoing workshops for Rwandan hospital staff reduced secondary transmission by 40 % compared with the first month of the outbreak.
• Research gap: Absence of a licensed vaccine underscores the need for accelerated clinical trials of candidate Marburg vaccines (e.g., VSV‑ΔG‑MARV).

---

Frequently Asked Questions (FAQ)

Question	Answer
Is there a risk of a Marburg outbreak in the U.S.?	Current data show a low risk; no community transmission and strict travel advisories are in place.
Can I get the Marburg vaccine?	No licensed vaccine is available; participation in experimental trials is limited to designated research centers.
What should I do if I develop symptoms after returning from Rwanda?	Contact your healthcare provider immediately, mention recent travel, and self‑isolate until evaluated.
How does Marburg differ from ebola?	Both are filoviruses with similar hemorrhagic presentations, but Marburg’s natural reservoir is the egyptian fruit bat, while Ebola’s includes several bat species and non‑human primates.

---

Reference sources (accessed 21 Dec 2025):

• Centers for Disease Control and Prevention (CDC). Marburg Virus Disease – 2025 Outbreak Update. https://www.cdc.gov/marburg/2025-outbreak
• World Health Institution (WHO). Marburg virus disease – Rwanda situation report, March 2025. https://www.who.int/emergencies/marburg-rwanda-2025
• Rwanda Ministry of Health. National Response Plan for Marburg Virus Disease, 2025. https://www.moh.gov.rw/marburg-response